



03C06

ATTORNEY'S DOCKET NO: B0801/7202 (AWS)


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Weiner et al.
Serial No: 09/809,745
Filed: March 15, 2001
For: SUPPRESSION OF VASCULAR DISORDERS BY MUCOSAL
ADMINISTRATION OF HEAT SHOCK PROTEIN PEPTIDES

Examiner: Unknown
Art Unit: Unknown

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to Commissioner for Patents, Washington, D.C. 20231, on the 6th day of June, 2001.


Alan W. Steele, Reg. No.: 45,128

Commissioner for Patents
Washington, D.C. 20231

Sir:

Transmitted herewith are the following documents:

- ☒ Information Disclosure Statement with References Cited
- ☒ Form PTO-1449
- ☒ Return Receipt Postcard


If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617)720-3500, Boston, Massachusetts.

If a fee is determined to be required, please charge the fee to the account of the undersigned, Deposit Account No. 23/2825. A duplicate of this sheet is enclosed.

Respectfully submitted,
Weiner et al., Applicants

By: 
Alan W. Steele, Reg. No. 45,128
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, MA 02210
Telephone (617) 720-3500

Docket No. B0801/7202 (AWS)
Dated: June 6, 2001



ATTORNEY'S DOCKET NO: B0801/7202 (AWS)


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Weiner et al.
Serial No: 09/809,745
Filed: March 15, 2001
For: SUPPRESSION OF VASCULAR DISORDERS BY MUCOSAL
ADMINISTRATION OF HEAT SHOCK PROTEIN PEPTIDES

Examiner: Unknown
Art Unit: Unknown

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to Commissioner for Patents, Washington, D.C. 20231, on the 6th day of June, 2001.



Alan W. Steele, Reg. No.: 45,128

Commissioner for Patents
Washington, D.C. 20231

**STATEMENT FILED PURSUANT TO THE DUTY OF
DISCLOSURE UNDER 37 CFR §§1.56, 1.97 AND 1.98**

Sir:


Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, the Applicant requests consideration of this Information Disclosure Statement.

PART I: Compliance with 37 C.F.R. §1.97

This Information Disclosure Statement has been filed within three months of the filing date of a National Application and before the mailing date of a first Office Action on the merits in the above-identified case. No fee or certification is required.

PART II: Information Cited

The Applicant hereby makes of record in the above-identified application the information listed on the attached form PTO-1449 (modified). The order of presentation of the references should not be construed as an indication of the importance of the references.



PART III: Remarks

copy of each of the above-identified information is enclosed unless otherwise indicated on the attached form PTO-1449 (modified). It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
2. The enclosed form PTO-1449 be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application;
3. The citations for the information be printed on any patent which issues from this application.

By submitting this Information Disclosure Statement, the Applicant makes no representation that a search has been performed, of the extent of any search performed, or that more relevant information does not exist.


By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.


Notwithstanding any statements by the Applicant, the Examiner is urged to form his own conclusion regarding the relevance of the cited information.

An early and favorable action is hereby requested.

Respectfully submitted,
Weiner et al., Applicants

By: 
Alan W. Steele, Reg. No. 45,128
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, MA 02210
Telephone (617) 720-3500

Docket No. B0801/7202 (AWS)
Dated: June 6, 2001
X June 15, 2001




| | | | |
|--|---|-----------------------------|------------------------------|
| FORM PTO-1449/A and B (Modified) | | APPLICATION NO.: 09/809,745 | ATTY. DOCKET NO.: B0801/7202 |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | FILING DATE: March 15, 2001 | |
| | | APPLICANT: Weiner et al. | |
| | | GROUP ART UNIT: unknown | EXAMINER: unknown |
| Sheet | 1 | of | 4 |

U.S. PATENT DOCUMENTS

| Examiner's Initials# | Cite No. | U.S. Patent Document | | Name of Patentee or Applicant of Cited Document | Date of Publication or of issue of Cited Document MM-DD-YYYY |
|-------------------------|-------------|----------------------|--------------|--|--|
| | | Number | Kind Code | | |
| | A1 | 3,561,444 | | Boucher | 02-09-1971 |
| | A2 | 3,699,963 | | Zaffaroni | 10-24-1972 |
| | A3 | 3,703,173 | | Dixon | 11-21-1972 |
| | A4 | 3,944,064 | | Bashaw et al. | 03-16-1976 |
| | A5 | 3,948,262 | | Zaffaroni | 04-06-1976 |
| | A6 | 3,993,073 | | Zaffaroni | 11-23-1976 |
| | A7 | 4,226,848 | | Nagai et al. | 10-07-1980 |
| | A8 | 4,309,404 | | DeNeale et al. | 01-05-1982 |
| | A9 | 4,309,406 | | Guley et al. | 01-05-1982 |
| | A10 | 4,556,552 | | Porter et al. | 12-03-1985 |
| | A11 | 4,624,251 | | Miller | 11-25-1986 |
| | A12 | 4,635,627 | | Gam | 01-13-1987 |
| | A13 | 4,675,189 | | Kent et al. | 06-23-1987 |
| | A14 | 4,704,295 | | Porter et al. | 11-03-1987 |
| | A15 | 4,713,243 | | Schiraldi et al. | 12-15-1987 |
| | A16 | 4,837,027 | | Lee et al. | 06-06-1989 |
| | A17 | 4,895,724 | | Cardinal et al. | 01-23-1990 |
| | A18 | 4,917,895 | | Lee et al. | 04-17-1990 |
| | A19 | 4,940,587 | | Jenkins et al. | 07-10-1990 |
| | A20 | 4,985,253 | | Fujioka et al. | 01-15-1991 |
| | A21 | 5,110,597 | | Wong et al. | 05-05-1992 |
| | A22 | 5,141,750 | | Lee et al. | 08-25-1992 |
| | A23 | 5,151,272 | | Engstrom et al. | 09-29-1992 |
| | A24 | 5,236,704 | | Fujioka et al. | 08-17-1993 |
| | A25 | 5,284,660 | | Lee et al. | 02-08-1994 |
| | A26 | 5,354,691 | | Van Eden et al. | 10-11-1994 |
| | A27 | 5,356,635 | | Raman et al. | 10-18-1994 |
| | A28 | 5,371,109 | | Engstrom et al. | 12-06-1994 |
| | A29 | 5,405,619 | | Santus et al. | 04-11-1995 |
| | A30 | 5,416,071 | | Igari et al. | 05-16-1995 |
| | A31 | 5,641,474 | | Hafler et al. | 06-24-1997 |
| | A32 | 5,840,855 | | Shinnick et al. | 11-24-1998 |
| | A33 | 5,856,305 | | Lucietto et al. | 01-05-1999 |
| | A34 | 5,869,054 | | Weiner et al. | 02-09-1999 |
| | A35 | 5,869,093 | | Weiner et al. | 02-09-1999 |
| | A36 | 5,961,977 | | Hafler et al. | 10-05-1999 |

FOREIGN PATENT DOCUMENTS

| Examiner's Initials# | Cite No. | Foreign Patent Document | | | Name of Patentee or Applicant of Cited Document (not necessary) | Date of Publication of Cited Document MM-DD-YYYY | Translation (Y/N) |
|-------------------------|-------------|-------------------------|-----------|--------------|---|---|----------------------|
| | | Office/ Country | Number | Kind Code | | | |
| | B1 | EPO | EP 205282 | B1 | | 09-13-1995 | |
| | B2 | EPO | EP 259013 | B1 | | 06-05-1991 | |




| | | | |
|--|---|-----------------------------|------------------------------|
| FORM PTO-1449/A and B (Modified) | | APPLICATION NO.: 09/809,745 | ATTY. DOCKET NO.: B0801/7202 |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | FILING DATE: March 15, 2001 | |
| | | APPLICANT: Weiner et al. | |
| | | GROUP ART UNIT: unknown | EXAMINER: unknown |
| Sheet | 2 | of | 4 |

| | | | | | | | |
|--|-----|------|------------|----|--|------------|--|
| | B3 | EPO | EP 354742 | B1 | | 03-16-1994 | |
| | B4 | EPO | EP 516141 | B1 | | 08-14-1996 | |
| | B5 | WIPO | WO85/02092 | A1 | | 05-23-1985 | |
| | B6 | WIPO | WO88/10120 | A1 | | 12-29-1988 | |
| | B7 | WIPO | WO91/01333 | A1 | | 02-07-1991 | |
| | B8 | WIPO | WO95/11011 | A1 | | 04-27-1995 | |
| | B9 | WIPO | WO95/15191 | A1 | | 06-08-1995 | |
| | B10 | WIPO | WO95/27499 | A1 | | 10-19-1995 | |
| | B11 | WIPO | WO95/27500 | A1 | | 10-19-1995 | |
| | B12 | WIPO | WO00/20019 | A2 | | 04/13/2000 | |
| | | | | | | | |

OTHER ART — NON PATENT LITERATURE DOCUMENTS

| Examiner's Initials# | Cite No | Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published. | Translation (Y/N) |
|----------------------|---------|--|-------------------|
| | C1 | AFEK A et al., Immunization of low-density lipoprotein receptor deficient (LDL-RD) mice with heat shock protein 65 (HSP-65) promotes early atherosclerosis. <i>J Autoimmun.</i> 2000 Mar;14(2):115-21. | |
| | C2 | DAHIYAT BI et al., De novo protein design: fully automated sequence selection. <i>Science.</i> 1997 Oct 3;278(5335):82-7. | |
| | C3 | GEORGE J et al., Enhanced fatty streak formation in C57BL/6J mice by immunization with heat shock protein-65. <i>Arterioscler Thromb Vasc Biol.</i> 1999 Mar;19(3):505-10. | |
| | C4 | GEORGE J et al., Requisite role for interleukin-4 in the acceleration of fatty streaks induced by heat shock protein 65 or Mycobacterium tuberculosis. <i>Circ Res.</i> 2000 Jun 23;86(12):1203-10. | |
| | C5 | HUNTER et al., The gastric emptying of hard gelatin capsules. <i>Int J Pharmaceutics.</i> 1983; 17:59-64. | |
| | C6 | JINDAL S et al., Primary structure of a human mitochondrial protein homologous to the bacterial and plant chaperonins and to the 65-kilodalton mycobacterial antigen. <i>Mol Cell Biol.</i> 1989 May;9(5):2279-83. | |
| | C7 | KALMAN S et al., Comparative genomes of Chlamydia pneumoniae and C. trachomatis. <i>Nat Genet.</i> 1999 Apr;21(4):385-9. | |
| | C8 | KAUFMANN SH, Heat shock proteins and the immune response. <i>Immunol Today.</i> 1990 Apr;11(4):129-36. | |
| | C9 | KEREN P et al., Effect of hyperglycemia and hyperlipidemia on atherosclerosis in LDL receptor-deficient mice: establishment of a combined model and association with heat shock protein 65 immunity. <i>Diabetes.</i> 2000 Jun;49(6):1064-9. | |
| | C10 | KIKUTA LC et al., Isolation and sequence analysis of the Chlamydia pneumoniae GroE operon. <i>Infect Immun.</i> 1991 Dec;59(12):4665-9. | |
| | C11 | KOL A et al., Chlamydial and human heat shock protein 60s activate human vascular endothelium, smooth muscle cells, and macrophages. <i>J Clin Invest.</i> 1999 Feb;103(4):571-7. | |
| | C12 | KOL A et al., Chlamydial heat shock protein 60 localizes in human atheroma and regulates macrophage tumor necrosis factor-alpha and matrix metalloproteinase expression. <i>Circulation.</i> 1998 Jul 28;98(4):300-7. | |
| | C13 | KOL A et al., Cutting edge: heat shock protein (HSP) 60 activates the innate immune response: CD14 is an essential receptor for HSP60 activation of mononuclear cells. <i>J Immunol.</i> 2000 Jan 1;164(1):13-7. | |
| | C14 | LINDQUIST S, The heat-shock response. <i>Annu Rev Biochem.</i> 1986;55:1151-91. | |
| | C15 | MACH F et al., Reduction of atherosclerosis in mice by inhibition of CD40 signalling. <i>Nature.</i> 1998 Jul 9;394(6689):200-3. | |
| | C16 | MARON R et al., Mucosal administration of HSP 65 decreases atherosclerosis and inflammation in the aortic arch of LDL receptor deficient mice. AAI/CIS Joint Annual Meeting, Seattle, WA, 12-16 May 2000; <i>FASEB J.</i> 2000 Apr 20;14(6):A1199. (ABSTRACT No. 183.9). | |



| | | | | | |
|--|---|-----------------------------|---|------------------------------|--|
| FORM PTO-1449/A and B (Modified) | | APPLICATION NO.: 09/809,745 | | ATTY. DOCKET NO.: B0801/7202 | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | FILING DATE: March 15, 2001 | | | |
| | | APPLICANT: Weiner et al. | | | |
| | | GROUP ART UNIT: unknown | | EXAMINER: unknown | |
| Sheet | 3 | of | 4 | | |

| | | | |
|-----|---|--|--|
| C17 | MERRIFIELD RB, Peptide synthesis on a solid polymer. <i>Fed Proc Am Soc Exp Biol.</i> 1962;21:412 (ABSTRACT). | | |
| C18 | MERRIFIELD RB, Solid phase peptide synthesis. I. The synthesis of a tetrapeptide. <i>J Am Chem Soc.</i> 1963 Jul 20; 85:2149-54. | | |
| C19 | METZLER B et al., Inhibition of arteriosclerosis by T-cell depletion in normocholesterolemic rabbits immunized with heat shock protein 65. <i>Arterioscler Thromb Vasc Biol.</i> 1999 Aug;19(8):1905-11. | | |
| C20 | MITCHELL AR et al., tert-Butoxycarbonylaminoacyl-4-(oxymethyl)-phenylacetamidomethyl-resin, a more acid-resistant support for solid-phase peptide synthesis. <i>J Am Chem Soc.</i> 1976 Nov 10;98(23):7357-62. | | |
| C21 | MORIMOTO RI, Heat shock: the role of transient inducible responses in cell damage, transformation, and differentiation. <i>Cancer Cells.</i> 1991 Aug;3(8):295-301. | | |
| C22 | NICOLETTI A et al., Immunomodulation of atherosclerosis: myth and reality. <i>J Intern Med.</i> 2000 Mar;247(3):397-405. | | |
| C23 | NOVER L, HSFs and HSPs--a stressful program on transcription factors and chaperones. Stress Proteins and the Heat Shock Response, sponsored by Cold Spring Harbor Laboratory, Cold Spring Harbor, NY USA, April 29-May 2, 1991. <i>New Biol.</i> 1991 Sep;3(9):855-9. | | |
| C24 | PELHAM HR, Heat shock and the sorting of luminal ER proteins. <i>EMBO J.</i> 1989 Nov;8(11):3171-6. | | |
| C25 | PELHAM HR, Speculations on the functions of the major heat shock and glucose-regulated proteins. <i>Cell.</i> 1986 Sep 26;46(7):959-61. | | |
| C26 | QIAO JH et al., Pathology of atheromatous lesions in inbred and genetically engineered mice. Genetic determination of arterial calcification. <i>Arterioscler Thromb.</i> 1994 Sep;14(9):1480-97. | | |
| C27 | SHINNICK TM, The 65-kilodalton antigen of Mycobacterium tuberculosis. <i>J Bacteriol.</i> 1987 Mar;169(3):1080-8. | | |
| C28 | SHOENFELD Y et al., Atherosclerosis as an infectious, inflammatory and autoimmune disease. <i>Trends Immunol.</i> 2001 Jun;22(6):293-5. | | |
| C29 | SHOENFELD Y et al., Heat shock protein 60/65, beta 2-glycoprotein I and oxidized LDL as players in murine atherosclerosis. <i>J Autoimmun.</i> 2000 Sep;15(2):199-202. | | |
| C30 | SMART JD et al., An in-vitro investigation of mucosa-adhesive materials for use in controlled drug delivery. <i>J Pharm Pharmacol.</i> 1984 May;36(5):295-9. | | |
| C31 | THOLE JE et al., Characterization, sequence determination, and immunogenicity of a 64-kilodalton protein of Mycobacterium bovis BCG expressed in escherichia coli K-12. <i>Infect Immun.</i> 1987 Jun;55(6):1466-75. | | |
| C32 | WICK G et al., Role of heat shock protein 65/60 in the pathogenesis of atherosclerosis. <i>Int Arch Allergy Immunol.</i> 1995 May-Jun;107(1-3):130-1. | | |
| C33 | XU Q et al., Increased expression of heat shock protein 65 coincides with a population of infiltrating T lymphocytes in atherosclerotic lesions of rabbits specifically responding to heat shock protein 65. <i>J Clin Invest.</i> 1993 Jun;91(6):2693-702. | | |
| C34 | XU Q et al., Induction of arteriosclerosis in normocholesterolemic rabbits by immunization with heat shock protein 65. <i>Arterioscler Thromb.</i> 1992 Jul;12(7):789-99. | | |
| C35 | XU Q et al., Regression of arteriosclerotic lesions induced by immunization with heat shock protein 65-containing material in normocholesterolemic, but not hypercholesterolemic, rabbits. <i>Atherosclerosis.</i> 1996 Jun;123(1-2):145-55. | | |
| C36 | YUAN Y et al., Monoclonal antibodies define genus-specific, species-specific, and cross-reactive epitopes of the chlamydial 60-kilodalton heat shock protein (hsp60): specific immunodetection and purification of chlamydial hsp60. <i>Infect Immun.</i> 1992 Jun;60(6):2288-96. | | |

| | | | | | |
|--|---|-----------------------------|---|------------------------------|--|
| FORM PTO-1449/A and B (Modified) | | APPLICATION NO.: 09/809,745 | | ATTY. DOCKET NO.: B0801/7202 | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | FILING DATE: March 15, 2001 | | | |
| | | APPLICANT: Weiner et al. | | | |
| | | GROUP ART UNIT: unknown | | EXAMINER: unknown | |
| Sheet | 4 | of | 4 | | |

| | |
|----------|-----------------|
| EXAMINER | DATE CONSIDERED |
|----------|-----------------|

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - Must provide a copy of any patent, publication, other information listed, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]